Central centrifugal cicatricial alopecia (CCCA) is the most common form of scarring alopecia in women of African descent, and it remains underdiagnosed. Unlike androgenetic alopecia or alopecia areata, CCCA destroys hair follicles permanently through progressive fibrosis, replacing them with scar tissue that can never produce hair again. Early detection changes outcomes dramatically, because treatment can only halt the process, not reverse the damage already done. BaldingAI helps you document crown changes over time with consistent photo tracking, which can give both you and your dermatologist objective data on whether the affected area is expanding.
TL;DR
- CCCA is a progressive scarring alopecia that begins at the crown vertex and spreads outward centrifugally.
- Prevalence estimates range up to 17% of Black women (Olsen et al. 2011), though many cases go undiagnosed.
- Clinical signs include a shiny smooth scalp at the vertex, reduced follicular openings, tenderness, and premature breakage.
- Genetic mutations in PADI3 (identified by Malki et al. 2019) may compromise the inner root sheath and increase susceptibility.
- Diagnosis requires a scalp biopsy showing lymphocytic inflammation and perifollicular fibrosis. Treatment focuses on stopping inflammation before more follicles are lost.
Important
This article is educational and not medical advice. If you are worried about sudden shedding, scalp symptoms, or side effects, talk to a licensed clinician.
What is CCCA?
CCCA is a primary lymphocytic cicatricial alopecia, meaning it involves immune-mediated inflammation that targets hair follicles and replaces them with fibrous scar tissue. The term “central centrifugal” describes its hallmark pattern: hair loss begins at the central scalp (crown vertex) and radiates outward symmetrically. “Cicatricial” means scarring. Once a follicle is destroyed by fibrosis, it cannot regenerate.
The condition was historically described under various names, including “hot comb alopecia” and “follicular degeneration syndrome,” before the North American Hair Research Society standardized the classification in 2001. That older terminology contributed to a misconception that styling practices alone cause the disease. Current evidence points to a more complex interplay of genetic predisposition, styling-related trauma, and inflammatory processes.
How common is CCCA?
CCCA disproportionately affects women of African descent. Olsen et al. published a cross-sectional study in 2011 in the Journal of the American Academy of Dermatology that examined 529 African American women presenting for routine dermatology visits. They found clinical evidence of CCCA in approximately 5.6% of the cohort, but estimated that prevalence could reach up to 17% when including subclinical cases and those who had not sought care.
A 2016 study by Dlova et al. in British Journal of Dermatology found similar prevalence rates among South African women, suggesting that the condition is not limited to one geographic population but is linked to shared genetic factors across the African diaspora. CCCA most commonly presents between ages 30 and 55, though cases have been documented in women as young as their early twenties.
Clinical signs to watch for
CCCA tends to progress slowly, which is part of why it often goes undetected until significant follicular loss has occurred. The earliest signs are subtle and can be mistaken for normal thinning or breakage.
The first visible change is usually thinning at the crown vertex, centered near the posterior midline of the scalp. The affected area shows a characteristic smooth, shiny appearance where follicular ostia (the tiny openings where hair exits the skin) are absent or markedly reduced. This differs from androgenetic alopecia, where the scalp surface retains visible pore openings even as the hairs miniaturize.
Tenderness or a prickling sensation at the crown is a common early symptom. Some patients describe itching or a “crawling” sensation. These symptoms correlate with active inflammation around the follicles and often precede visible hair loss. If you experience persistent scalp tenderness at the vertex, that alone warrants a dermatology consultation.
Premature hair breakage at the crown is another early indicator. Hairs in the affected zone may break at or near the scalp surface, creating short stubs that are sometimes mistaken for new growth. On dermoscopy (trichoscopy), a dermatologist will typically see a “lonely hair” sign, where isolated single hairs remain in areas of otherwise complete follicular loss, along with a white-grey halo around follicular remnants indicating perifollicular fibrosis.
The genetic connection: PADI3 mutations
For decades, CCCA was attributed primarily to hairstyling practices: chemical relaxers, tight braids, heat straightening. While these factors contribute to follicular stress, they do not explain why the majority of women who use these practices never develop CCCA.
In 2019, Malki et al. published a landmark study in the New England Journal of Medicine identifying mutations in the PADI3 gene in a significant proportion of CCCA patients. PADI3 encodes peptidylarginine deiminase type III, an enzyme that modifies proteins in the inner root sheath of the hair follicle. The inner root sheath acts as a structural scaffold that guides the growing hair shaft upward through the follicle. When PADI3 is dysfunctional, the inner root sheath becomes fragile and fails to support proper hair growth.
This structural vulnerability means that mechanical and chemical insults that a normal follicle could withstand, such as tension from braiding or the alkaline pH of chemical relaxers, may trigger an inflammatory cascade in a genetically susceptible follicle. The current understanding is that CCCA likely results from a “two-hit” model: genetic predisposition plus environmental triggers.
How CCCA differs from other types of hair loss
Distinguishing CCCA from androgenetic alopecia (AGA) and alopecia areata (AA) is critical because the treatment approaches are entirely different. AGA involves follicular miniaturization driven by dihydrotestosterone (DHT) sensitivity. The follicles shrink but remain alive and capable of recovery with treatment. In CCCA, follicles are destroyed and replaced by scar tissue. No amount of minoxidil or finasteride will bring back a scarred follicle.
Alopecia areata is an autoimmune condition that causes patchy, non-scarring hair loss. The patches in AA tend to be well-circumscribed with “exclamation point” hairs at the margins and a smooth but non-shiny scalp surface. AA patches can appear anywhere on the scalp, while CCCA is characteristically centered at the vertex. The follicles in AA remain intact beneath the surface and can resume growth once the immune attack subsides.
CCCA also shares features with frontal fibrosing alopecia (FFA), another form of cicatricial alopecia. Both are lymphocyte-mediated scarring conditions, but FFA predominantly affects the frontal hairline and eyebrows and is most common in postmenopausal women, while CCCA centers at the crown and primarily affects Black women in their thirties to fifties.
Diagnostic workup
A clinical examination and trichoscopy can raise strong suspicion for CCCA, but definitive diagnosis requires a scalp biopsy. The biopsy is typically taken from the active border of the affected area (not the central scar, where follicles are already destroyed) and processed with both horizontal and vertical sectioning.
Histopathological findings characteristic of CCCA include lymphocytic inflammation centered around the upper follicle (the infundibulum and isthmus), premature desquamation of the inner root sheath, lamellar fibroplasia (concentric layers of collagen replacing the follicle), and eccentric thinning of the follicular epithelium. In later stages, the follicle is entirely replaced by a fibrous tract, often with a naked hair shaft embedded in scar tissue (a finding sometimes called “follicular dropout”).
A pull test (gently pulling a cluster of 40 to 60 hairs) is usually negative in CCCA because the hairs in the affected zone have already broken off or been destroyed. This contrasts with active alopecia areata or telogen effluvium, where the pull test is typically positive.
Treatment approach
The goal of CCCA treatment is to halt active inflammation and prevent further follicular destruction. No treatment can restore follicles that have already been replaced by scar tissue, which is why early intervention is so important.
First-line medical therapy typically includes a combination of topical corticosteroids (high-potency, such as clobetasol propionate 0.05%) applied to the active border of the affected area, and oral anti-inflammatory antibiotics. Doxycycline 100 mg twice daily is the most commonly prescribed oral agent, used not for its antibacterial properties but for its anti-inflammatory effects on matrix metalloproteinases and cytokine modulation. Treatment courses typically run for three to six months, with reassessment at each interval.
For patients with significant symptoms or rapid progression, intralesional triamcinolone acetonide injections (typically 5 to 10 mg/mL) can deliver concentrated anti-inflammatory medication directly to the affected follicles. These injections are usually performed every four to six weeks. Some clinicians add topical minoxidil 5% to support the remaining unaffected follicles and maximize density in areas where follicles are miniaturized but not yet scarred.
Equally important is modifying hair care practices. Reducing tension from tight hairstyles (braids, weaves, extensions that pull on the central scalp), minimizing chemical relaxer use, and lowering heat styling frequency can all reduce mechanical and chemical stress on vulnerable follicles. This does not mean abandoning cultural hairstyling practices entirely. It means working with a dermatologist to identify which specific practices are contributing the most traction and chemical damage to the crown area.
Why early detection matters
CCCA is irreversible once scarring has occurred. A follicle replaced by fibrotic tissue will not respond to any topical or systemic medication. The only window for intervention is while active inflammation is present and follicles are still structurally intact but under threat.
This makes regular scalp monitoring particularly valuable for women at higher risk. Photographing the crown vertex every two to four weeks with standardized lighting and angles creates a visual timeline that can reveal expansion of the affected area before it becomes obvious in daily life. BaldingAI provides structured scan tracking that keeps lighting, angle, and hair state consistent, giving you and your clinician comparable data points over time.
If you notice increasing smoothness at the crown, loss of visible follicular openings, persistent tenderness, or unexplained breakage concentrated at the vertex, schedule a dermatology appointment. A biopsy can confirm or rule out CCCA, and if confirmed, early treatment can preserve the follicles that remain.
Monitor your crown over time
BaldingAI helps you track vertex changes with consistent photo scans, so you can catch early warning signs and share objective data with your dermatologist.
Your scans stay private. Delete or export anytime.
Sources: Olsen et al. 2011, Journal of the American Academy of Dermatology, Malki et al. 2019, New England Journal of Medicine, Dlova et al. 2016, British Journal of Dermatology.
